The Pharmagellan Guide to Biotech Forecasting and Valuation - by Frank S David & Seth Robey & Andrew Matthews (Paperback)

About the Book

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser-or aspire to be one-then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. The Pharmagellan Guide is a comprehensive, thoroughly referenced handbook for early-stage biopharma assets and companies.

Book Synopsis

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser--or aspire to be one--then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.

THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.

- Vetted benchmarks for key drivers of income, expenses, and valuation.
- Proprietary analyses by Pharmagellan's experienced consulting team.
- More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.

Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.

Review Quotes

"Deserves a spot on the bookshelf of every biotech CFO." -Bruce Booth, Partner, Atlas Venture "A helpful and insightful resource for anyone who finds themselves staring at a blank Excel spreadsheet." -Adam Feuerstein, Senior Columnist, TheStreet.com "A fantastic plain-English guide to building a valuation model for a biotech product or portfolio. It manages to be both conversational and rigorous, citing primary data supporting the assumptions made throughout-and encourages you to do the same. If you're trying to develop a reasonable view of the value of your program or your company-and a view that will appear reasonable to the folks across the table-whether it's to support a financing, a licensing transaction, an acquisition, or just dreaming about what your company will be worth some day-this beautiful book breaks it down for you." -Michael Gilman, Advisor, Atlas Venture; serial biotech CEO (Stromedix, Padlock Therapeutics) "An invaluable, rigorously detailed, and well-validated guide to assessing drug development programs and opportunities-certain to raise biotech analysts' confidence in their models and forecasts." -John Sullivan, Director of Equity Research and Healthcare Investment Strategist, Leerink Partners "Pragmatic, credible advice on financial modeling for biotech executives. This is the book I wish I'd had when I started out in the industry-it would have saved me hours of time." -Vin Milano, CEO, Idera Pharmaceuticals "To be a successful investor in biotechnology requires a grasp of medicine, familiarity with a company's management team, and the ability to translate that knowledge into complex quantitative models. Price and value are often two very different things, so you need to always have your own opinion about the latter precisely modeled. The Pharmagellan Guide to Biotech Forecasting and Valuation does an excellent job of defining the inputs that go into modeling, explains how they can be forecasted, and shows how it all ties together. I'd recommend it to anyone looking to better understand one of the most difficult sides of this business." -Brad Loncar, CEO, Loncar Investments "Clear, well-written, and very useful in our mission to better serve our patients." -Jim Geraghty, Chairman of the Board of Directors, Idera Pharmaceuticals "This book offers a great explanation of the inputs and assumptions for biotech models, and how to think about them. I highly recommend it, both to people who build the models and people like me who have to look at them." -Briggs Morrison, CEO, Syndax Pharmaceuticals